Nippon Shinyaku said on September 19 that the US FDA has granted orphan drug designation to its investigational Duchenne muscular dystrophy (DMD) therapy NS-051/NCNP-04.NS-051/NCNP-04 is an antisense oligonucleotide discovered by the company jointly with the National Center of Neurology and…
To read the full story
Related Article
- Nippon Shinyaku Gets FDA’s Rare Pediatric Disease Tag for DMD Drug
January 24, 2025
BUSINESS
- Oral Flu Drugs Prescribed to 2.46 Million in February as Cases Surge Again: Intage
March 17, 2026
- ADDP, Proteros Tie Up to Expand Drug Discovery Support
March 17, 2026
- Personal iPSC Service to Launch with Production Cost in the 10-Million-Yen Range
March 17, 2026
- Olumiant Gains Oral Suspension Formulation in Japan
March 17, 2026
- BMS Japan “On Track” to Double Sales by 2032 as Launch Wave Nears
March 17, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





